Rinucumab

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Rinucumab
Monoclonal antibody
Type?
SourceHuman
Targetplatelet-derived growth factor receptor beta
Clinical data
SynonymsREGN2176
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6472H9974N1710O2022S38
Molar mass145.3 kg/mol g·mol−1

Rinucumab (REGN2176) is a monoclonal antibody designed for the treatment of neovascular age-related macular degeneration.[1]

This drug was developed by Regeneron Pharmaceuticals, Inc.

References[edit]